Abstract
Background High right ventricular (RV) pacing burden can result in pacing-induced cardiomyopathy (PICM).
Objectives To investigate whether ACE inhibitors (ACEI), angiotensin receptor blockers (ARB), and beta blockers (BB) reduce the risk of PICM in patients with high RV pacing burden.
Methods This was a single center, retrospective study which included patients with normal ejection fraction (EF) and complete heart block who underwent pacemaker implantation between 1992 and 2013. The medical therapy group included patients who received ACEI/ARB, BB, or combination of these classes. The control group received neither ACEI/ARB nor BB. The primary endpoint was PICM, defined as upgrade to a biventricular device or reduction in EF to ≤40% without another etiology identified. Fine-Gray subdistribution hazard models accounting for death as a competing risk were used to determine the relationship between medical therapy (ACEI/ARB, BB, or combination) and cumulative incidence of PICM.
Results The study included 642 patients (mean [SD] age 71 [14] years; 51% women). Over 10 years of follow-up, 76 (11.8%) patients received ACEI/ARB therapy only; 49 (7.6%) received BB therapy only; and 86 (13.4%) were exposed to both. PICM occurred in 10 of 211 patients in the medical therapy group (4.7%) and in 30 of 431 in the control group (7.0%). In adjusted analyses weighted for group-switching, the risk of PICM was significantly lower in the medical therapy group compared to the control group (HR 0.59, 95% CI 0.45 – 0.77). Patients exposed to combination therapy had the lowest risk (HR 0.46, 95% CI 0.31 – 0.69).
Conclusion In patients with high RV pacing burden, BB therapy alone or in combination with ACEI/ARBs appears to reduce the risk of PICM within 10 years of pacemaker implantation.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This was a retrospective trial and thus not registered on ClinicalTrials.gov. Institutional IRB approval was obtained for the study.
Funding Statement
There was no funding obtained for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Wake Forest IRB approved this research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
Funding: None
Disclosures: None
Data Availability
The data that was used for the analysis of this study is available in a de-identified format on request from the corresponding author. The data are not publicly available due to HIPAA and patient privacy.
Abbreviations
- PICM
- pacing induced cardiomyopathy
- RV
- right ventricle
- PPM
- permanent pacemaker
- CRT
- cardiac resynchronization therapy
- ACEI
- ACE inhibitors
- ARB
- angiotensin receptor blockers
- BB
- beta blockers
- EF
- ejection fraction
- AV
- atrioventricular
